Do you want to read an article? Please log in or register.
Proactive brain screening using contrast-enhanced brain CT scans in HER2+ metastatic breast cancer
Breast Cancer
Related content
SABCS 2025
Breast Cancer
DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer
Breast Cancer
Association of recurrence patterns and outcome with HR and HER2 status in patients with resected brain metastases from breast cancer
Int J Cancer
Weller J, Katzendobler S, Thiele F, Riesberg A, Harter PN, Klauschen F, Wuerstlein R, Schoenecker S, Escudero MP, Forbrig R, Thon N, Ringel F, Weller M, Le Rhun E, Stoecklein VM
doi: 10.1002/ijc.70407
Breast Cancer
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
Clin Cancer Res
Jhaveri K, Eli LD, Hurvitz SA, Brufsky A, Bose R, de Miguel M, Unni N, Reid S, Quinn DI, Mahalingam D, Saura Manich C, García-Sáenz JÁ, Martínez-Bueno A, Guerrero-Zotano A, Trédan O, Wildiers H, Bischof GF, Bebchuk J, Solit DB
doi: 10.1158/1078-0432.CCR-25-4135
Breast Cancer
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort
Eur J Cancer
Bouteiller F, Gourgou S, Bringuier M, Galvin A, Mailliez A, Bertrand N, Hung M, Frenel JS, Massard V, Bachelot T, Pflumio C, Gonçalves A, Levy C, Bosquet L, Jacot W, Delaloge S, Grinda T, Bellera C
doi: 10.1016/j.ejca.2025.116166
Breast Cancer
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer
Clin Cancer Res
Rugo HS, Kaklamani V, McArthur H, Wander SA, Gradishar W, Mahtani R, Pegram M, Lustberg M, Swallow E, Maitland J, Kloss S, Wasserman T, Tolaney SM
doi: 10.1158/1078-0432.CCR-25-3040
Breast Cancer
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer
Eur J Cancer
Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Belleville E, Wimberger P, Enzinger HM, Huebner H, Uhrig S, Hack CC, Krabisch P, Fasching PA, Wuerstlein R, Untch M, Ditsch N, Hein A, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, Goossens C, Engler T
doi: 10.1016/j.ejca.2025.115689
RECOMMENDED
Breast Cancer
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
O'Brien KM, House MG, Goldberg M, Jones ME, Weinberg CR, de Gonzalez AB, Bertrand KA, Blot WJ, DeHart JC, Couch FJ, Garcia-Closas M, Giles GG, Kirsh VA, Kitahara CM, Koh WP, Park HL, Milne RL, Palmer JR, Patel AV, Rohan TE, Schoemaker MJ, Swerdlow AJ, Teras LR, Vachon C, Visvanathan K, Yuan JM, Zheng W, Nichols HB, Sandler DP
doi: 10.1016/S1470-2045(25)00211-6
Breast Cancer
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
Lancet Oncol
Yao H, Zhang Q, Li H, Yin Y, Wang S, Ouyang Q, Sun T, Li W, Wang X, Yan M, Wang B, Cheng J, Tong Z, Wei W, Wang X, Xie W, Sun Z, Yuan P, Geng C, Gan L, Han X, Li W, Zhou S, Yan X, Gao J, Yi T, Wu J, Niu Z, Fu F, Nie J, Wang Y, Zhao B, Wu Z, Zhu Z, Yang Y, Zhao J, Sheng Z, Zhang Y, Cheng L, Zhu X, Song E
doi: 10.1016/S1470-2045(26)00193-2
Breast Cancer
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
Ann Oncol
Saura C, Cortés J, Modi S, Kim SB, Hamilton E, Hurvitz SA, Krop IE, Curigliano G, Iwata H, Im SA, Herbolsheimer P, Karnoub M, Boran A, Kuwahara Y, Egorov A, André F
doi: 10.1016/j.annonc.2025.11.007